MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 162401-32-3
MCE 国际站:Roflumilast
产品活性:Roflumilast (APTA-2217) 是一种选择性的 PDE4 抑制剂,作用于 PDE4A1,PDEA4,PDEB1 和 PDEB2,IC50 分别为 0.7,0.9,0.7 和 0.2 nM。
研究领域:Metabolic Enzyme/Protease | Anti-infection
作用靶点:Phosphodiesterase (PDE) | RSV
In Vitro: Roflumilast does not affect PDE enzymes apart from PDE4, and is a subnanomolar inhibitor of most PDE4 splicing variants tested. It showed no PDE4 subtype selectivity apart from PDE4C (4C1, IC50=3 nM; 4C2, IC50=4.3 nM), which is inhibited with a slightly lower potency. Roflumilast is a potent and selective PDE4 inhibitor. Roflumilast is a monoselective PDE4 inhibitor since it does not affect other PDE isoenzymes, including PDE1, PDE2, PDE3, and PDE5 up to 10,000-fold higher concentrations. Roflumilast inhibits human neutrophil functions. Roflumilast inhibits TNFα synthesis in monocyte-derived dendritic cells. Rolfumilast inhibits proliferation and cytokine synthesis in CD4+ T cells. Proliferation is inhibited to a maximum of about 60% by Roflumilast with a potency (IC30) of 7 nM.
In Vivo: Animal studies with Roflumilast demonstrated that it reduced the accumulation of neutrophils in bronchoalveolar lavage fluid following short-term exposure of guinea pigs, mice or rats to tobacco smoke, and following exposure of rats to a combination of tobacco smoke and bacterial lipopolysaccharide, and abolished the lung parenchymal influx of inflammatory cells seen in rats exposed to tobacco smoke for 7 months. Roflumilast blocks COPD progression in pIgR?/? mice. For these studies, 9-month-old WT or pIgR?/? mice are treated daily by oral gavage with 100 μg of Roflumilast (5 μg/g) or vehicle (4% methylcellulose, 1.3% PEG400) for 3 months and lungs are harvested at 12 months of age. Unlike pIgR?/? mice treated with vehicle, mice treated with Roflumilast had no progression of small airway wall remodelling after starting treatment. Strikingly, 12-month-old pIgR?/? mice treated with Roflumilast had reduced indices of emphysema compared with 9-month-old pIgR?/? mice, indicating that Roflumilast not only blocks progression of emphysema in this model but apparently facilitates some resolution of the emphysematous destruction of lung parenchyma.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Immunology/Inflammation Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Alzheimer's Disease Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Neurodegenerative Disease-related Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | EMA-Approved Drug Library | Human Metabolite Library | Off-patent Drug Library | Highly Selective Inhibitors Library | Cirsimarin | PDE11-IN-1 | Enpp-1-IN-2 | PAT-347 | Vardenafil-d5 | Bay 60-7550 | BMS-433771 | Deltarasin hydrochloride | HA155 | Apremilast | Enpp-1-IN-6 | RS-25344 hydrochloride | PDE4-IN-6 | Sp-cAMPS | ITI-214 | Irsenontrine maleate | Lodenafil | Osoresnontrine | Deltasonamide 2 | RSV604 (R enantiomer) | Ribavirin | PF-07038124 | Ziritaxestat | ATX inhibitor 22 | Milrinone-d3 | Avanafil-13C,d3 | MT-3014 | ATX inhibitor 19 | Homo Sildenafil-d5
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。